Non-nucleoside reverse transcriptase inhibitors

Details Non-nucleoside reverse transcriptase inhibitors Non-nucleoside reverse transcriptase inhibitors

2011-03-15

2011-03-15

Chu, Yong (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S263200, C548S263400

Reexamination Certificate

active

07906540

ABSTRACT:
Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

REFERENCES:
patent: 3274185 (1966-09-01), Sigal et al.
patent: 3813384 (1974-05-01), Vogelsang et al.
patent: 4826990 (1989-05-01), Musser et al.
patent: 4942236 (1990-07-01), Musser et al.
patent: 5103014 (1992-04-01), Musser et al.
patent: 5331002 (1994-07-01), Miller
patent: 5436252 (1995-07-01), Sorensen et al.
patent: 6140499 (2000-10-01), Fortunak et al.
patent: 6248769 (2001-06-01), Cavalla et al.
patent: 0 435 177 (1991-07-01), None
patent: 0 273 309 (1995-01-01), None
patent: 0 273 310 (1995-06-01), None
patent: 60 215675 (1985-10-01), None
patent: 60215675 (1985-10-01), None
patent: WO 96/13264 (1996-05-01), None
patent: WO 97/40017 (1997-10-01), None
patent: WO 98/04135 (1998-02-01), None
patent: WO 02/38553 (2002-05-01), None
patent: WO 2004/074257 (2004-09-01), None
patent: WO 2004/085406 (2004-10-01), None
patent: WO 2005/102989 (2005-11-01), None
patent: WO 2006/010545 (2006-02-01), None
Patini et al, Chem. Rev., 96(8), 1996, pp. 3147-3176, esp. p. 3149.
Translation of JP 60215675, Oct. 1985, Akita et al., see pp. 17-19 in particular.
Buckheit, R. W., Jr. “Non-Nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection,”Expert Opinion(2001) vol. 10 (8) p. 1423-1442.
De Clercq, E. “New Developments in Anti-HIV Chemotherapy,”Current Medicinal Chemistry(2001) vol. 8, p. 1543-1572.
Del Olmo, E. et. al. “Anti-Trypanosoma Activity of Some Natural Stilbenoids and Synthesis Related Heterocyclic Compounds,”Bioorganic&Med. Chem. Lett.(2001) vol. 11, p. 2755-2757.
Rosen G. H., et. al. “2-Benzyl-1,3,4-oxadiazolin-5-one and related compounds,”Journal of Heterocyclic Chemistry(1971) p. 659-662.
Wilder Smith, A.E. “Preparation of some New 4-Substituted Derivatives of p-Amino-o-hydroxy-phenyl-1,3,4-oxadizolone-5 and Study of their Mycobacteriostatic Properties,”Arzneim-forschung(1967) vol. 67 (17), p. 768-772.
Yuksek, H., et. al. “Synthesis and Antibacterial Activities of some 4,5-Dihydro-1H-1,2,4-triazol-5-ones,”Arzneim-forschung(1997) vol. 47 (4), p. 405-409.

Affiliated with

Also associated with

Rating

Non-nucleoside reverse transcriptase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non-nucleoside reverse transcriptase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-nucleoside reverse transcriptase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2675068